GlassScriptPhysician profile
Jonathan Perry Goodwin
NPI 1336738293
$5,502.26
in general payments reported to CMS, 2019-2025
27 companies · $1,783 in 2025
The $1,783 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,472 · 2024: $2,248 · 2025: $1,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,364 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,363.59 |
| Education | $138.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,130.79 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $946.30 | 2023-2025 | |
| Csl Behring | $700.54 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Biocryst US Sales Co., LLC | $381.29 | 2023-2025 | Orladeyo, Orladeyo |
| Regeneron Healthcare Solutions, INC. | $348.65 | 2023-2024 | Dupixent |
| Genentech USA, INC. | $342.93 | 2023-2025 | Xolair |
| Blueprint Medicines Corporation | $273.68 | 2023-2025 | Ayvakit |
| Alk-Abello, INC | $229.36 | 2023 | Ragwitek, Grastek, Odactra |
| Glaxosmithkline, LLC. | $188.80 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech, INC. | $149.98 | 2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $106.24 | 2024 | |
| Amgen INC. | $99.21 | 2023-2025 | Tezspire |
| Optinose US, INC. | $85.34 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $81.32 | 2025 | Neffy |
| Pfizer INC. | $68.09 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $67.76 | 2024-2025 | Hyqvia, Takhzyro |
| Greer Laboratories, INC. | $53.35 | 2023-2024 | Oralair |
| Abbvie INC. | $49.40 | 2025 | |
| Pharming Healthcare, INC. | $38.41 | 2025 | Ruconest |
| Galderma Laboratories, L.P. | $30.79 | 2025 | Nemluvio |
| Mylan Specialty L.P. | $24.12 | 2024 | Yupelri |
| Kaleo, INC. | $20.49 | 2023 | Auvi-Q |
| Valinor Pharma, LLC | $19.35 | 2025 | Movantik |
| Appliedvr INC | $18.32 | 2025 | Relievrx |
| Hikma Pharmaceuticals USA | $17.63 | 2025 | Ryaltris |
| Gc Biopharma USA, INC. | $15.64 | 2025 | Alyglo |
| Currax Pharmaceuticals LLC | $14.48 | 2024 | Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Goodwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.